IRWD - Ironwood Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.28
+0.02 (+0.11%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.26
Open18.22
Bid17.33 x 800
Ask19.25 x 800
Day's Range18.00 - 18.43
52 Week Range12.89 - 21.20
Volume477,758
Avg. Volume1,146,825
Market Cap2.8B
Beta1.36
PE Ratio (TTM)N/A
EPS (TTM)-0.75
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.79
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEventsyesterday

    Edited Transcript of IRWD earnings conference call or presentation 6-Aug-18 12:30pm GMT

    Q2 2018 Ironwood Pharmaceuticals Inc Earnings Call

  • Here’s What Tesaro’s Valuation Trend Indicates
    Market Realist2 days ago

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.

  • Analysts’ Expectations for Tesaro and Its Peers in August
    Market Realist2 days ago

    Analysts’ Expectations for Tesaro and Its Peers in August

    Tesaro (TSRO) is a commercial-stage biopharmaceutical company primarily focused on developing treatments for solid tumors by using small molecules and immune-oncology antibodies both as monotherapies and in combinations. Tesaro’s key product, Zejula, has been approved in the United States as well as the European Union as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tesaro commercialized Zejula in the United States in April 2017 and in Europe in December 2017.

  • How Is Bausch Health’s Salix Pharmaceuticals Positioned?
    Market Realist2 days ago

    How Is Bausch Health’s Salix Pharmaceuticals Positioned?

    Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter compared to $387 million in the second quarter of 2017, which reflected ~14% YoY (year-over-year) growth.

  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realist3 days ago

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Analysts Remain Bullish on Nektar Stock in August
    Market Realist4 days ago

    Analysts Remain Bullish on Nektar Stock in August

    Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.

  • Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
    Zacks4 days ago

    Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

    Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.

  • GlobeNewswire9 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Omnicom Group, Ironwood Pharmaceuticals, CorEnergy Infrastructure Trust, Cypress Semiconductor, Yum! Brands, and Zendesk — New Research Emphasizes Economic Growth

    NEW YORK, Aug. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Omnicom ...

  • Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down
    Zacks11 days ago

    Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down

    Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.

  • Ironwood Pharmaceuticals (IRWD) Reports Q2 Loss, Lags Revenue Estimates
    Zacks12 days ago

    Ironwood Pharmaceuticals (IRWD) Reports Q2 Loss, Lags Revenue Estimates

    Ironwood (IRWD) delivered earnings and revenue surprises of -47.37% and -9.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press12 days ago

    Ironwood: 2Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 32 cents per share. Losses, adjusted for amortization costs and non-recurring costs, came to 28 cents per share. The results fell short ...

  • Business Wire12 days ago

    Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update

    – Second quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS® U.S. net sales of $192 million and commercial margin of 60% –

  • ACCESSWIRE12 days ago

    Ironwood Pharmaceuticals, Inc. Class A to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Ironwood Pharmaceuticals, Inc. Class A (NASDAQ: IRWD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 8:30 ...

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit14 days ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding IRWD totaled $454 million.

  • Business Wire26 days ago

    Ironwood Pharmaceuticals to Host Second Quarter 2018 Investor Update Call

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced it will host its second quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Monday, August 6, 2018. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 5795089. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

  • ACCESSWIRElast month

    Initiating Free Research Reports on Horizon Pharma and Three Other Healthcare Equities

    LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Business Wirelast month

    Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

    Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced the initiation of a Phase IIIb clinical trial evaluating the efficacy and safety of linaclotide 290 mcg on multiple abdominal symptoms in addition to pain, including bloating and discomfort, in adult patients with irritable bowel syndrome with constipation (IBS-C). Linaclotide is a guanylate cyclase-C (GC-C) agonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC).

  • See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWD

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Ironwood Pharmaceuticals and Aerie Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 25, 2018 / U.S. markets were mixed Friday, with the Dow snapping an eight day losing streak as energy shares rallied. However, major indexes experienced weekly losses on ...

  • Business Wire2 months ago

    Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific Sessions

    Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today presented additional data from an exploratory Phase IIa study of praliciguat (IW-1973) in patients with type 2 diabetes and hypertension during an oral session at the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, Fla. Praliciguat is an oral, once-daily soluble guanylate cyclase (sGC) stimulator that is currently being studied in Phase II clinical trials in patients with diabetic nephropathy and in patients with heart failure with preserved ejection fraction (HFpEF). Building on previously announced top-line data from the Phase IIa randomized, placebo-controlled, 14-day study, which showed that treatment with praliciguat led to reductions in blood pressure, fasting plasma glucose, cholesterol levels and triglycerides in patients on a stable regimen of medicines to manage their disease, the newly reported findings also suggested that praliciguat improved insulin sensitivity.

  • Ironwood Initiates Phase III Studies on Reflux Candidate
    Zacks2 months ago

    Ironwood Initiates Phase III Studies on Reflux Candidate

    Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.

  • Business Wire2 months ago

    Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease

    Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced the initiation of two Phase III clinical trials evaluating the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD). Persistent GERD affects an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton pump inhibitors (PPIs), the current standard of care. “We are excited to advance development of IW-3718 by initiating the Phase III trials,” said Christopher Wright, M.D., Ph.D., senior vice president, global development and chief development officer at Ironwood.

  • Business Wire2 months ago

    Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions

    Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotechnology company, today announced that the company will present clinical and preclinical data for the company’s soluble guanylate cyclase (sGC) stimulator praliciguat (IW-1973) during the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, Fla., June 22 through June 26, 2018. Praliciguat is currently being studied in Phase II clinical trials in patients with diabetic nephropathy and in patients with heart failure with preserved ejection fraction (HFpEF). Data from a Phase IIa 14-day study of praliciguat in patients with diabetes and hypertension will be featured as an oral presentation during the Emerging Targets for Diabetes Treatment session, presented by John P. Hanrahan, M.D., M.P.H., of Ironwood.

  • ACCESSWIRE2 months ago

    Free Research Reports on Ironwood Pharma and Three More Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on IRWD sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com observes the recent performance of Horizon Pharma PLC (NASDAQ: HZNP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Lipocine Inc. (NASDAQ: LPCN), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN).

  • Alex Denner adds Ironwood Pharma and Medicines Co. to bes...
    CNBC Videoslast month

    Alex Denner adds Ironwood Pharma and Medicines Co. to bes...

    CNBC's Dominic Chu reports on Sarissa Capital Management's Alex Denner presenting his best investment ideas at Delivering Alpha.